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Background
In times of financial hardship, making innovative treat-
ments affordable for society, accessible for patients and
profitable for pharmaceutical companies is a challenge.
Reimbursement is often threatened by uncertainties
about the financial impact or evidence for a treatment.
A contractual agreement between the payer and phar-
maceutical company can link reimbursement to financial
thresholds (financial-based agreements) or performance
of a drug (performance-based agreements). The aim of
this study was to investigate the experience with con-
tractual agreements in Belgium.
Methods
Qualitative research was performed to obtain insights into
the perspectives of different stakeholders. Semi-structured
interviews were conducted between September and
December 2014. Interviewees were recruited through pur-
posive sampling. Interviews were audio-recorded, verbatim
transcribed and analyzed using the grounded theory
approach.
Results
Sixteen interviews were conducted, involving three repre-
sentatives of the National Institute of Health and Disability
Insurance (NIHDI), three representatives of sickness
funds, seven representatives of a pharmaceutical company
or pharmaceutical industry association, and three health
care providers. All parties indicate that contractual agree-
ments allow real-life data generation for treatments that
would not be accessible for patients otherwise. The major-
ity of agreements applied in Belgium establish financial
compensations that a pharmaceutical company needs to
accomplish in order to get a treatment reimbursed, with
limited role for performance based aspects. Financial com-
pensations remain confidential while the list price stays
artificially high. The Belgian list prices influence other
European prices due to the external reference pricing sys-
tem. Industry representatives feel like financial based
agreements are the only way to keep up the list price of
the treatment. Representatives of the NIHDI notify the
financial security that these agreements provide, while
more data generation is allowed. In the light of financial
based agreements, all stakeholders question the inherent
meaning of the list price with regard to the value of the
drug and the influence on external reference pricing. All
parties emphasize that more attention for the added value
of the treatment and a shift to more performance based
agreements is required, although several hurdles still need
to be conquered. Given current evolutions towards earlier
market access, such as adaptive pathways and medical
need programs, development of performance based
schemes is a must.
Conclusions
The European external reference price system drives the
application of financial based agreements but at the
same time, the value of the list price becomes meaning-
less. All stakeholders show eagerness for development
and application of performance based agreements.
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